Sarcouncil Journal of Medical Sciences

Abstract: Statistical programming teams are often staffed as though the work performed at every clinical trial phase were interchangeable. Headcount, timeline, and study volume tend to drive resourcing decisions far more than the underlying nature of the analytical task itself does. We examined published regulatory guidance, technical practice literature, and documented industry reporting describing statistical programming activity across Phase I through Phase IV of drug development, comparing the analytical, validation, and regulatory demands characteristic of each phase against four resourcing-relevant dimensions. This study aims to determine whether a structured, phase-specific practice framework can better inform how programming resources, particularly seniority and specialization, should be allocated across a development program. Dataset complexity, validation burden, and regulatory exposure increase sharply and unevenly from Phase I through Phase III, where dual-programming validation practice alone can increase programming effort by 60 to 100 percent, then shift in kind rather than degree at Phase IV, where real-world evidence competencies begin to dominate. Generic, headcount-based resourcing approaches appear to systematically understate the seniority and specialization requirements of later-phase and post-marketing programming work. We outline the practical implications for how statistical programming managers plan staff assignments across a drug’s lifecycle.